23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

Home DNA testing firm 23andMe is placing the blame on customers who reused login credentials for a cyber incident in which 6.9 million customers' data was exposed.

23andMe blames users for data breach, citing recycled passwords

Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1

23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts

Two days before 23andMe disclosed that hackers had accessed the personal and genetic data of almost seven million customers, the genetic testing giant updated its terms of service.

23andMe changes to terms of service are ‘cynical' and ‘self-serving,' lawyers say

23andMe (NASDAQ: ME) stock price has had a remarkable fall from grace amid sustained unprofitability and a recent hack that could cost it millions of dollars. After peaking at $18.15 in February 2021, the shares have plunged to below $1.

Is it safe to buy the 23andMe (ME) stock price dip?

The updates are meant to “streamline arbitration proceedings where multiple similar claims are filed,” the company said in a note to users. DNA testing service 23andme has changed the dispute resolution and arbitration section of its terms of service on the heels of a hack that saw the data of roughly half of its users impacted.

23andMe just updated its ‘dispute resolution' rules as fallout from a serious data breach continues

Apple

A roundup of the stories we've been following closely. Everyone is searching for a remote job.

Today's top business headlines: Apple's stock, ChatGPT basics, and 23andMe's scary hack

NEW YORK , Dec. 5, 2023 /PRNewswire/ -- 23andMe, a popular personal genomics and DNA analysis company run by 23andMe Holding Co. ("23 and Me") (NASDAQ: ME), recently suffered a massive data leak. The attack targeted the personal information of 23andMe users -more than 4 million people- compromising individual's personal information such as full name, birth year, email address, and sex, along with information on genetic ancestry, potential relatives, and geolocation.

INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation Of 23andMe Holding Co (NASDAQ: ME) Data Breach

US company says ‘threat actor' responsible for security breach that affected nearly half of its 14m reported users

Genetic testing firm 23andMe admits hackers accessed DNA data of 7m users

An October data breach at the personal genomics company appears to be much worse than originally reported. Here's what we know so far.

23andMe hacked: Was my ancestry or DNA data impacted?

23andMe, the DNA testing company, admitted Monday that a data breach in October accessed the personal information of millions more users' personal data than originally announced.  On Friday, the company said that hackers accessed the personal data of 14,000 customers, or about 0.1% of users, as well as “a significant number of files containing profile information about other users' ancestry.

23andMe says 6.9 million users had personal data accessed by hackers

DNA-testing company 23andMe confirmed Monday that information about 6.9 million people, about half of its 14 million customers, was accessed illegally.

23andMe confirms hackers accessed ancestry data of 6.9 million people

On Friday, genetic testing company 23andMe announced that hackers accessed the personal data of 0.1% of customers, or about 14,000 individuals. The company also said that by accessing those accounts, hackers were also able to access “a significant number of files containing profile information about other users' ancestry.

23andMe confirms hackers stole ancestry data on 6.9 million users

Genetic testing company 23andMe announced on Friday that hackers accessed around 14,000 customer accounts in the company's recent data breach. In a new filing with the U.S. Securities and Exchange Commission published Friday, the company said that, based on its investigation into the incident, it had determined that hackers had accessed 0.

23andMe says hackers accessed ‘significant number' of files about users' ancestry

Exact Sciences

Fulgent Genetics

If you're searching for digital health stocks to add to your portfolio, look no further. Technological innovation is leading to the increased digitalization and personalization of healthcare.

The 3 Best Digital Health Stocks for Personalized Medicine

23andMe Customers Are Urged to Contact Schubert Jonckheer & Kolbe LLP to Discuss Their Legal Rights SAN FRANCISCO , Nov. 13, 2023 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP today launched an investigation into 23andMe, a leading genetic-testing company, concerning a cyberattack involving customers' sensitive personal information. According to news reports, an attack on 23andMe's user data occurred on August 11, 2023.

PRIVACY ALERT: Genetic Testing Company 23andMe Faces Class Action Investigation for Cyberattack Potentially Impacting Five Million Customers

23andMe Holding Co. (NASDAQ:ME ) Q2 2024 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Ian Cooney - Senior Director, IR Anne Wojcicki - Chief Executive Officer and Co-Founder Joseph Selsavage - Interim Chief Financial and Accounting Officer Jennifer Low - Head of Therapeutics Bill Richards - Head of Therapeutics Discovery Conference Call Participants Chad Wiatrowski - TD Cowen David Lebowitz - Citigroup Inc. Operator Hello, and welcome to 23andMe's Fiscal Year 2024 Second Quarter Financial Results Conference Call. As a reminder, this call is being recorded.

23andMe Holding Co. (ME) Q2 2024 Earnings Call Transcript

Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin

23andMe Reports Second Quarter Fiscal 2024 Financial Results

DNA testing and genealogy companies are stepping up user account security by mandating the use of two-factor authentication, following the theft of millions of user records from DNA genetic testing giant 23andMe.

23andMe data theft prompts DNA testing companies to switch on 2FA by default

The Company's first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection The Company's first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced data from its ongoing first-in-human Phase 1/2a clinical trial evaluating the safety and efficacy of 23ME-00610, an investigational antibody targeting CD200R1. Updated data from the now completed dose escalation phase continue to showcase the manageable safety profile of 23ME-00610 at the dose levels tested, and highlight preliminary efficacy results in patients with advanced solid tumors.

23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

23andMe Holding Co. ME, +0.39% said Tuesday it's launching a health action plan that will offer its clients personalized recommendations based on genetic and other health data. The South San Francisco-based provider of home DNA kits said the plan will offer suggestions on modifying behavior related to sleep, diet and exercise, as well as on potential new treatments or activities for certain health conditions.

23andMe to offer clients personalized action plans based on genetic and other health data

23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe 23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe

23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data

Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe database for novel drug target discovery and other research Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe database for novel drug target discovery and other research

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) second quarter after the market closes on Wednesday, November 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2024 Second Quarter Financial Results

Since news of the hack, many customers have expressed worries their ethnicity and other sensitive information could be used against them if leaked.

News for 23andMe Stock (ME)